<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221672</url>
  </required_header>
  <id_info>
    <org_study_id>Terlipressin-Hepatectomy</org_study_id>
    <nct_id>NCT04221672</nct_id>
  </id_info>
  <brief_title>The Effect of Terlipressin on Recovery of Liver Function After Hepatectomy</brief_title>
  <official_title>Study on the Effect of Terlipressin on Recovery of Liver Function After Hepatectomy: a Multicenter Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Portal vein hypertension is associated with post-hepatectomy liver failure in patients with
      liver cirrhosis. Our previous study found that bolus injection of 1 mg terlipressin
      immediately after hepatectomy decreased portal vein pressure, and post-operative continuous
      use of terlipressin decreased the amount of abdominal drain. In this multicenter randomized
      controlled study, we aim to evaluate the effects of terlipressin in the patients who
      underwent liver resection complicated by portal vein hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Portal vein hypertension is associated with post-hepatectomy liver failure in patients with
      liver cirrhosis. Our previous study found that bolus injection of 1 mg terlipressin
      immediately after hepatectomy decreased portal vein pressure, and post-operative continuous
      use of terlipressin decreased the amount of abdominal drain. In this multicenter randomized
      controlled study, we aim to evaluate the effects of terlipressin in the patients who
      underwent liver resection complicated by portal vein hypertension. The primary outcome is the
      total abdominal drain on postoperative day (POD) 1 to 3. The secondary outcomes are: (1) the
      incidence of post-hepatectomy liver failure; (2) post-operative acute kidney injury; (3) the
      side effects of terlipressin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The total abdominal drainage</measure>
    <time_frame>From post-operative day 1 to day 4.</time_frame>
    <description>from postoperative day 1 through day 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of post-hepatectomy liver failure</measure>
    <time_frame>From post-operative day 1 to day 30.</time_frame>
    <description>based on the criteria of ISGLS 2011.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of acute kidney injury</measure>
    <time_frame>From post-operative day 1 to day 30.</time_frame>
    <description>defined as an absolute increase in serum creatinine (Cr) ≥ 0.3 mg/dl (26.5 μmol/L) and/or ≥ 50% from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The side effects of terlipressin</measure>
    <time_frame>From post-operative day 1 to day 30.</time_frame>
    <description>the incidences of abdominal pain, diarrhea, headache, hyponatremia, and hypertension</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Terlipressin Adverse Reaction</condition>
  <condition>Ascites Hepatic</condition>
  <condition>Liver Failure</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Terlipressin plus standard care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediately after hepatectomy, 1 mg terlipressin was given intravenously after hemostasis was achieved. After surgery, participants were routinely managed, and terlipressin were administrated at a dosage of 2 mg per day for 4 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants were not administrated with terlipressin during surgery and were routinely managed after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin plus standard care</intervention_name>
    <description>All the participants received routine care after surgery. Intraoperative 1 mg, and 1 mg q12h from post-operative day 1 through day 4.</description>
    <arm_group_label>Terlipressin plus standard care</arm_group_label>
    <other_name>terlipressin infusion plus routine care</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>All the participants received routine care after surgery only.</description>
    <arm_group_label>Standard care</arm_group_label>
    <other_name>routine care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects signed informed consent.

          -  An open liver resection is planned.

          -  Hepatitis B virus infection background.

          -  Pre-operative liver function is Child-Pugh A.

          -  Subjects with clinical significance portal vein hypertension or the liver stiffness &gt;
             12 kPa before surgery.

          -  Portal vein pressure &gt; 12 mmHg at 5 min after liver resection.

        Exclusion Criteria:

          -  Age &lt; 18 y or &gt; 75 y.

          -  Subjects received anti-cancer therapy within 3 months before surgery, or with a
             history of open or laparoscopic surgery.

          -  Portal vein tumor thrombus was confirmed by preoperative imaging study.

          -  Obstruction of biliary tract.

          -  Pre-operative ALT or AST &gt; 2×ULN.

          -  A history of myocardial infarction or chronic kidney disease.

          -  Severe arrhythmia.

          -  Intraoperative portal vein pressure could not be measured technically.

          -  Any other contraindications of the terlipressin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui-Chuan Sun, MD&amp;PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao-Dong Zhu, MD&amp;PhD</last_name>
    <phone>+862164041990</phone>
    <email>zhuxiaodong@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital Affiliated To Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongjun Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiao-Dong Zhu</last_name>
      <phone>+862164041990</phone>
      <email>zhuxiaodong@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hui-Chuan Sun, MD&amp;PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital Affiliated to Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiandong Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200438</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Shen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, Bernardi M, Romanelli RG, Colletta C, Salinas F, Di Giacomo A, Ridola L, Fornasiere E, Caraceni P, Morando F, Piano S, Gatta A, Angeli P; Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology. 2015 Aug;62(2):567-74. doi: 10.1002/hep.27709. Epub 2015 Feb 13.</citation>
    <PMID>25644760</PMID>
  </reference>
  <reference>
    <citation>Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, Koch M, Makuuchi M, Dematteo RP, Christophi C, Banting S, Usatoff V, Nagino M, Maddern G, Hugh TJ, Vauthey JN, Greig P, Rees M, Yokoyama Y, Fan ST, Nimura Y, Figueras J, Capussotti L, Büchler MW, Weitz J. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011 May;149(5):713-24. doi: 10.1016/j.surg.2010.10.001. Epub 2011 Jan 14.</citation>
    <PMID>21236455</PMID>
  </reference>
  <reference>
    <citation>Chen X, Zhai J, Cai X, Zhang Y, Wei L, Shi L, Wu D, Shen F, Lau WY, Wu M. Severity of portal hypertension and prediction of postoperative liver failure after liver resection in patients with Child-Pugh grade A cirrhosis. Br J Surg. 2012 Dec;99(12):1701-10. doi: 10.1002/bjs.8951.</citation>
    <PMID>23132418</PMID>
  </reference>
  <reference>
    <citation>Saner FH, Canbay A, Gerken G, Broelsch CE. Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome. Expert Rev Gastroenterol Hepatol. 2007 Dec;1(2):207-17. doi: 10.1586/17474124.1.2.207. Review.</citation>
    <PMID>19072411</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatectomy</keyword>
  <keyword>terlipressin</keyword>
  <keyword>liver failure</keyword>
  <keyword>acute kidney injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

